Citation Impact
Citing Papers
Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.
1992
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
The implications of angiogenesis for the biology and therapy of cancer metastasis
1994 Standout
Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres
2002 StandoutNobel
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma
2006
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
Marriage and health: His and hers.
2001 Standout
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
IFN-treatment of B16-F1 versus B16-F10: Relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread
1988
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice
2002 StandoutNobel
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Role of Biochemical Mediators in Clinical Nutrition and Surgical Metabolism
1988
Cushing's syndrome
2015 Standout
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
1990 Standout
Renal-Cell Carcinoma
1996 Standout
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
Paclitaxel (Taxol)
1995 Standout
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis
1996 Standout
Transfusion‐associated cancer recurrence and postoperative infection: meta‐analysis of randomized, controlled clinical trials
1996
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
1988
Interferons and Their Stimulated Genes in the Tumor Microenvironment
2014
Anthrazykline in der Krebstherapie
1997 Standout
Microbial synthesis of poly(ε-lysine) and its various applications
2004 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Machine learning applications in cancer prognosis and prediction
2014 Standout
Transfusion Medicine — Blood Transfusion
1999 Standout
Anthracycline Antibiotics in Cancer Therapy
1994
Molecular mechanisms of cisplatin resistance
2011 Standout
Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
1995
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide
1989
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
1995
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
1993 Standout
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
1994
In search of the ‘missing self’: MHC molecules and NK cell recognition
1990 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Sarcoidosis
1997 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Increased Levels of Serum Interferon-gamma in Pulmonary Sarcoidosis and Relationship with Response to Corticosteroid Therapy
1991
Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors
2013
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
1988 Standout
High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
1990
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma
1992
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: “Maintenance” therapy reconsidered
1992
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Pre-operative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery
1998
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
1996
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Cancer of the Ovary
2004 Standout
Local and Systemic Effects of Intradermal Recombinant Interferon-γ in Patients with Lepromatous Leprosy
1986 StandoutNobel
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.
1989 Standout
Adriamycin
1974 Standout
Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide.
1985
Prognostic factors in advanced ovarian carcinoma.
1986
Clinical pharmacology of intraperitoneal cisplatin
1985
Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
1986
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.
1980
Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes.
1987
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
1986
Childhood and adolescent cancer statistics, 2014
2014 Standout
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide
1972
Ovarian cancer: new clinical approaches
1991
Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung—assessment of clinical implications in patients on combination chemotherapy
1981
Advanced Ovarian Cancer: Long-Term Results of Treatment with Intensive Cisplatin-Based Chemotherapy of Brief Duration
1988
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
1979 Standout
A system for the surgical staging of musculoskeletal sarcoma.
1981 Standout
Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model
1988 StandoutScience
Phase I trial of recombinant interferon gamma in cancer patients.
1986
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.
1985
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
The pharmaceutics and delivery of therapeutic polypeptides and proteins
1993
Chemotherapy with or without Radiation Therapy in Limited Small-Cell Carcinoma of the Lung
1987
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.
1985
The biology of cancer metastasis and implications for therapy
1987
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
1988 Standout
A clinicopathologic analysis of adriamycin cardiotoxicity
1973 Standout
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
1990
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
Considerations in the Design of Possible Cell Cycle Effective Drugs
1986
The Anthracycline Antineoplastic Drugs
1981 Standout
Treatment selection for cancer patients: Application of statistical decision theory to the treatment of advanced ovarian cancer
1985
Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report.
1984
Ovarian cancer in the elderly: An analysis of Surveillance, Epidemiology, and End Results Program data
1986
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
1986
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
1992 StandoutScience
Works of Oldham Rk being referenced
Tumor products and potential markers in small cell lung cancer.
1978
Custom-tailored drug immunoconjugates in cancer therapy.
1991
Cell-mediated cytotoxicity against human tumors: lessons learned and future prospects.
1983
Small cell lung cancer: progress and perspectives.
1978
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
1981
Treatment of Ewing's sarcoma with adriamycin (NSC-123127).
1972
Natural killer cells: history, relevance, and clinical applications.
1990
Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma.
1989
Biologicals and biological response modifiers: fourth modality of cancer treatment.
1984
Biologicals and biological response modifiers: design of clinical trials.
1985
Effects of recombinant interferon-alpha on immune function in cancer patients.
1983
A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer.
1984
Immunotherapy: the old and the new.
1983
Gamma-interferon: physiology and speculation on its role in medicine.
1987
Biology of cancer therapy: some new insights into adjuvant treatment of metastatic solid tumors.
1983
Interferon as a biological response modifying agent in clinical trials.
1983
Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer.
1982